Oral Session 2-9C Multiple Myeloma: Basic (Novel Molecular Targets）

[OS2-9C-4] Combined inhibition of HDAC and Akt as a strategy to overcome multi-drug resistant multiple myeloma

Mitsuhito Hirano¹, Yoichi Imai², Takahiko Murayama³, Kota Sato⁴, Junichi Yamamoto⁵, Muneyoshi Futami^1,2, Masaki Ri^6,7, Takumi Ito⁵, Hiroshi Yasui^2,8, Noriko Gotoh³, Shinsuke Iida⁶, Hiroshi Handa⁵, Arinobu Tojo^1,2 (1.Division of Molecular Therapy, IMSUT, 2.Department of Hematology/Oncology, IMSUT Hospital, 3.Division of Cancer Cell Biology Cancer Research Institute of Kanazawa University, 4.Department of Hematology, Japanese Red Cross Medical Center, 5.Department of Nanoparticle Translational Research, Tokyo Medical University, 6.Department of Hematology & Oncology, Nagoya City University, 7.Department of Blood Transfusion, Nagoya City University Hospital, 8.Fundamental Study on Cutting Edge of Genome Medicine, IMSUT)